Publications

  1. Caselli RJ, Langbaum J, Marchant GE, Lindor RA, Hunt KS, Henslin BR, Dueck AC, Robert JS. Public perceptions of presymptomatic testing for Alzheimer disease. Mayo Clin Proc. 2014 Oct; 89(10):1389-96. Epub 2014 Aug 26.
    View PubMed
  2. Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA. EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. Br J Cancer. 2014 Sep 9; 111(6):1065-71. Epub 2014 Aug 12.
    View PubMed
  3. Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014 Sep; 106(9). Epub 2014 Sep 29.
    View PubMed
  4. Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernandez-Maraver D, Dohner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Vannucchi AM, Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood. 2014 Jun 12; 123(24):3803-10. Epub 2014 Feb 19.
    View PubMed
  5. McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, Nunez-Nateras R, Castle EP, Gray RJ, Wasif N, Goetz MP, Hawse JR, Henry TJ, Barrett MT, Cunliffe HE, Pockaj BA. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol. 2014 Feb; 21(2):361-7. Epub 2013 Sep 18
    View PubMed
  6. McCullough AE, Dell'orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrighetto S, Chen B, Jackisch C, Untch M, Perez EA, Piccart-Gebhart MJ, Viale G. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. Breast Cancer Res Treat. 2014 Feb; 143(3):485-92. Epub 2014 Jan 07.
    View PubMed
  7. Patel SH, Hinni ML, Hayden RE, Wong WW, Dueck AC, Zarka MA, Curtis KK, Halyard MY. Transoral laser microsurgery followed by radiation therapy for oropharyngeal tumors: the Mayo Clinic Arizona experience. Head Neck. 2014 Feb; 36(2):220-5. Epub 2013 Mar 26
    View PubMed
  8. Stonnington CM, Chen K, Lee W, Locke DE, Dueck AC, Liu X, Roontiva A, Fleisher AS, Caselli RJ, Reiman EM. Fibrillar amyloid correlates of preclinical cognitive decline. Alzheimers Dement. 2014 Jan; 10(1):e1-8. Epub 2013 Apr 11
    View PubMed
  9. Caselli RJ, Locke DE, Dueck AC, Knopman DS, Woodruff BK, Hoffman-Snyder C, Rademakers R, Fleisher AS, Reiman EM. The neuropsychology of normal aging and preclinical Alzheimer's disease. Alzheimers Dement. 2014 Jan; 10(1):84-92. Epub 2013 Mar 26.
    View PubMed
  10. Grover ML, Edwards FD, Chang YH, Cook CB, Behrens MC, Dueck AC. Fracture risk perception study: patient self-perceptions of bone health often disagree with calculated fracture risk. Womens Health Issues. 2014 Jan-Feb; 24(1):e69-75.
    View PubMed
  11. Locke DE, Dueck AC, Stonnington CM, Knopman DS, Geda YE, Caselli RJ. Depressive symptoms in healthy apolipoprotein E epsilon4 carriers and noncarriers: a longitudinal study. J Clin Psychiatry. 2013 Dec; 74(12):1256-61.
    View PubMed
  12. Dueck AC, Reinholz MM, Geiger XJ, Tenner K, Ballman K, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow J, Harris LN, Ingle JN, Lingle WL, Perez EA. Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831. Clin Cancer Res. 2013 Oct 15; 19(20):5798-807. Epub 2013 Aug 21.
    View PubMed
  13. Tan WW, Dueck AC, Flynn P, Steen P, Anderson D, Rowland K, Northfelt D, Perez EA. N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial. Ann Oncol. 2013 Oct; 24(10):2548-54. Epub 2013 Jun 24.
    View PubMed
  14. Moreno-Aspitia A, Hillman DW, Dyar SH, Tenner KS, Gralow J, Kaufman PA, Davidson NE, Lafky JM, Reinholz MM, Lingle WL, Kutteh LA, Carney WP, Dueck AC, Perez EA. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831. Cancer. 2013 Aug 1; 119(15):2675-82. Epub 2013 Jun 06.
    View PubMed
  15. Slack JL, Dueck AC, Fauble VD, Sproat LO, Reeder CB, Noel P, Khera N, Betcher JA, Klein JL, Leis JF, Adams RH. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte ant igen mismatch. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1167-74. Epub 2013 May 7
    View PubMed
  16. Crozier JA, Moreno-Aspitia A, Ballman KV, Dueck AC, Pockaj BA, Perez EA. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. Cancer. 2013 Jul 1; 119(13):2447-54. Epub 2013 Apr 12.
    View PubMed
  17. Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, Lingle WL, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris LN, Gralow JR, Reinholz MM. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol. 2013 Jun 10; 31(17):2115-22. Epub 2013 May 06.
    View PubMed
  18. Reilly CM, Bruner DW, Mitchell SA, Minasian LM, Basch E, Dueck AC, Cella D, Reeve BB. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer. 2013 Jun; 21(6):1525-50. Epub 2013 Jan 12.
    View PubMed
  19. Moreno-Aspitia A, Dueck AC, Ghanem-Canete I, Patel T, Dakhil S, Johnson D, Franco S, Kahanic S, Colon-Otero G, Tenner KS, Rodeheffer R, McCullough AE, Jenkins RB, Palmieri FM, Northfelt D, Perez EA. RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(2):427-35. Epub 2013 Mar 12.
    View PubMed
  20. Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat. 2013 Feb; 138(1):99-108. Epub 2013 Feb 19.
    View PubMed
  21. Cleeland CS, Sloan JA, Cella D, Chen C, Dueck AC, Janjan NA, Liepa AM, Mallick R, O'Mara A, Pearson JD, Torigoe Y, Wang XS, Williams LA, Woodruff JF, CPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force. Recommendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force. Cancer. 2013 Jan 15; 119(2):411-20. Epub 2012 Aug 28.
    View PubMed
  22. Zhang W, Johnston JA, Ross MA, Sanniec K, Gleason EA, Dueck AC, Santello M. Effects of carpal tunnel syndrome on dexterous manipulation are grip type-dependent. PLoS One. 2013; 8(1):e53751. Epub 2013 Jan 10.
    View PubMed
  23. Sideras K, Dueck AC, Hobday TJ, Rowland KM Jr, Allred JB, Northfelt DW, Lingle WL, Behrens RJ, Fitch TR, Nikcevich DA, Perez EA. North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane. Clin Breast Cancer. 2012 Dec; 12(6):387-91. Epub 2012 Oct 17.
    View PubMed
  24. Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012 Nov 20; 30(33):4098-103. Epub 2012 Oct 15.
    View PubMed
  25. Karlin NJ, Dueck AC, Cook CB. Cancer with diabetes: prevalence, metabolic control, and survival in an academic oncology practice. Endocr Pract. 2012 Nov-Dec; 18(6):898-905.
    View PubMed
  26. Caselli RJ, Dueck AC, Huentelman MJ, Lutz MW, Saunders AM, Reiman EM, Roses AD. Longitudinal modeling of cognitive aging and the TOMM40 effect. Alzheimers Dement. 2012 Nov; 8(6):490-5.
    View PubMed
  27. McGhan LJ, Dueck AC, Gray RJ, Wasif N, McCullough AE, Pockaj BA. The changing landscape of axillary surgery: which breast cancer patients may still benefit from complete axillary lymph node dissection? J Surg Oncol. 2012 Sep 1; 106(3):254-9. Epub 2011 Oct 27.
    View PubMed
  28. Haakinson DJ, Leeds SG, Dueck AC, Gray RJ, Wasif N, Stucky CC, Northfelt DW, Apsey HA, Pockaj B. The impact of obesity on breast cancer: a retrospective review. Ann Surg Oncol. 2012 Sep; 19(9):3012-8. Epub 2012 Mar 27.
    View PubMed
  29. Hu LS, Eschbacher JM, Heiserman JE, Dueck AC, Shapiro WR, Liu S, Karis JP, Smith KA, Coons SW, Nakaji P, Spetzler RF, Feuerstein BG, Debbins J, Baxter LC. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro Oncol. 2012 Jul; 14(7):919-30. Epub 2012 May 03.
    View PubMed
  30. Ma I, Dueck A, Gray R, Wasif N, Giurescu M, Lorans R, Pizzitola V, Pockaj B. Clinical and self breast examination remain important in the era of modern screening. Ann Surg Oncol. 2012 May; 19(5):1484-90. Epub 2011 Dec 08.
    View PubMed
  31. Perez EA, Dueck AC, McCullough AE, Reinholz MM, Tenner KS, Davidson NE, Gralow J, Harris LN, Kutteh LA, Hillman DW, Jenkins RB, Chen B. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst. 2012 Jan 18; 104(2):159-62. Epub 2011 Dec 2
    View PubMed
  32. Hu LS, Eschbacher JM, Dueck AC, Heiserman JE, Liu S, Karis JP, Smith KA, Shapiro WR, Pinnaduwage DS, Coons SW, Nakaji P, Debbins J, Feuerstein BG, Baxter LC. Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol. 2012 Jan; 33(1):69-76. Epub 2011 Nov 17.
    View PubMed
  33. Zhang W, Johnston JA, Ross MA, Coakley BJ, Gleason EA, Dueck AC, Santello M. Effects of carpal tunnel syndrome on adaptation of multi-digit forces to object mass distribution for whole-hand manipulation. J Neuroeng Rehabil. 2012; 9:83. Epub 2012 Nov 21.
    View PubMed
  34. Paripati HR, Karlin NJ, Schild SE, Vora SA, Dueck AC, Ross HJ. Multimodality therapy improves survival in elderly patients with locally advanced non-small cell lung cancer-A retrospective analysis. Journal of Geriatric Oncology. 2012; 3(2):104-10.
  35. Borad MJ, Curtis KK, Babiker HM, Benjamin M, Tibes R, Ramanathan RK, Wright K, Dueck AC, Jameson G, Von Hoff DD. The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials. J Cancer. 2012; 3:345-53. Epub 2012 Aug 17.
    View PubMed
  36. Egnatios GL, Dueck AC, Macdonald JB, Laman SD, Warschaw KE, DiCaudo DJ, Nemeth SA, Sekulic A, Gray RJ, Wasif N, Pockaj BA. The impact of biopsy technique on upstaging, residual disease, and outcome in cutaneous melanoma. Am J Surg. 2011 Dec; 202(6):771-7; discussion 777-8. Epub 2011 Oct 13.
    View PubMed
  37. Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy V, LaPlant B, Allred JB, Stella PJ, Lingle WL, Perez EA. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin Cancer Res. 2011 Nov 15; 17(22):7183-93. Epub 2011 Oct 05.
    View PubMed
  38. Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD, Estrov Z, Verstovsek S. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011 Nov 1; 117(21):4869-77. Epub 2011 Apr 08.
    View PubMed
  39. Billar JA, Dueck AC, Gray RJ, Wasif N, Pockaj BA. Preoperative predictors of nipple-areola complex involvement for patients undergoing mastectomy for breast cancer. Ann Surg Oncol. 2011 Oct; 18(11):3123-8. Epub 2011 Aug 23.
    View PubMed
  40. Chakkera HA, Weil EJ, Swanson CM, Dueck AC, Heilman RL, Reddy KS, Hamawi K, Khamash H, Moss AA, Mulligan DC, Katariya N, Knowler WC. Pretransplant risk score for new-onset diabetes after kidney transplantation. Diabetes Care. 2011 Oct; 34(10):2141-5.
    View PubMed
  41. Sheikh F, Pockaj B, Wasif N, Dueck A, Gray RJ. Positive margins after breast-conserving therapy: localization technique or tumor biology? Am J Surg. 2011 Sep; 202(3):281-5. Epub 2011 May 19.
    View PubMed
  42. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011 Jul 14; 118(2):401-8. Epub 2011 May 02.
    View PubMed
  43. Stonnington CM, Locke DE, Dueck AC, Caselli RJ. Anxiety affects cognition differently in healthy apolipoprotein E epsilon4 homozygotes and non-carriers. J Neuropsychiatry Clin Neurosci. 2011 Summer; 23(3):294-9.
    View PubMed
  44. Craft RO, Rebecca AM, Flahive C, Casey WJ 3rd, Dueck A, Harold KL. Does size matter? Technical considerations of a regenerative tissue matrix for use in reconstructive surgery. Can J Plast Surg. 2011 Summer; 19(2):51-2.
    View PubMed
  45. Caselli RJ, Dueck AC, Locke DE, Hoffman-Snyder CR, Woodruff BK, Rapcsak SZ, Reiman EM. Longitudinal modeling of frontal cognition in APOE epsilon4 homozygotes, heterozygotes, and noncarriers. Neurology. 2011 Apr 19; 76(16):1383-8.
    View PubMed
  46. Caselli RJ, Dueck AC, Locke DE, Sabbagh MN, Ahern GL, Rapcsak SZ, Baxter LC, Yaari R, Woodruff BK, Hoffman-Snyder C, Rademakers R, Findley S, Reiman EM. Cerebrovascular risk factors and preclinical memory decline in healthy APOE epsilon4 homozygotes. Neurology. 2011 Mar 22; 76(12):1078-84. Epub 2011 Feb 16.
    View PubMed
  47. Grover M, Mookadam M, Armas D, Bozarth C, Castleberry T, Gannon M, Webb D, Dueck A. Identifying patients at risk for obstructive sleep apnea in a primary care practice. J Am Board Fam Med. 2011 Mar-Apr; 24(2):152-60.
    View PubMed
  48. Perez EA, Jenkins RB, Dueck AC, Wiktor AE, Bedroske PP, Anderson SK, Ketterling RP, Sukov WR, Kanehira K, Chen B, Geiger XJ, Andorfer CA, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow JR, Harris LN, Ingle JN, Lingle WL, C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol. 2011 Feb 20; 29(6):651-9. Epub 2011 Jan 18.
    View PubMed
  49. Zhang W, Johnston JA, Ross MA, Smith AA, Coakley BJ, Gleason EA, Dueck AC, Santello M. Effects of carpal tunnel syndrome on adaptation of multi-digit forces to object weight for whole-hand manipulation. PLoS One. 2011; 6(11):e27715. Epub 2011 Nov 16.
    View PubMed
  50. Kamal AH, Loprinzi CL, Reynolds C, Dueck AC, Geiger XJ, Ingle JN, Carlson RW, Hobday TJ, Winer EP, Goetz MP. Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. Oncologist. 2011; 16(10):1359-66. Epub 2011 Sep 20.
    View PubMed
  51. Macdonald JB, Dueck AC, Gray RJ, Wasif N, Swanson DL, Sekulic A, Pockaj BA. Malignant melanoma in the elderly: different regional disease and poorer prognosis. J Cancer. 2011; 2:538-43. Epub 2011 Nov 01.
    View PubMed
  52. Ferreira S, Shunk D, Collofello J, MacKulak G, Dueck A. Reducing the risk of requirements volatility: Findings from an empirical survey. Journal of Software Maintenance and Evolution. 2011; 23(5):375-93.
  53. Curtis KK, Ashman JB, Beauchamp CP, Schwartz AJ, Callister MD, Dueck AC, Gunderson LL, Fitch TR. Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities. Radiat Oncol. 2011; 6:91. Epub 2011 Aug 09.
    View PubMed
  54. Stucky CC, Gray RJ, Dueck AC, Wasif N, Laman SD, Sekulic A, Pockaj BA. Risk factors associated with local and in-transit recurrence of cutaneous melanoma. Am J Surg. 2010 Dec; 200(6):770-4; discussion 774-5.
    View PubMed
  55. Haakinson DJ, Stucky CC, Dueck AC, Gray RJ, Wasif N, Apsey HA, Pockaj B. A significant number of women present with palpable breast cancer even with a normal mammogram within 1 year. Am J Surg. 2010 Dec; 200(6):712-7; discussion 717-8.
    View PubMed
  56. Sprangers MA, Sloan JA, Barsevick A, Chauhan C, Dueck AC, Raat H, Shi Q, Van Noorden CJ, GENEQOL Consortium. Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes. Qual Life Res. 2010 Dec; 19(10):1395-403. Epub 2010 Oct 14.
    View PubMed
  57. Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, Dueck AC, Ketterling RP, Ingle JN, Lingle WL, Kaufman PA, Visscher DW, Jenkins RB. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol. 2010 Oct 1; 28(28):4307-15. Epub 2010 Aug 09.
    View PubMed
  58. Billar JA, Dueck AC, Stucky CC, Gray RJ, Wasif N, Northfelt DW, McCullough AE, Pockaj BA. Triple-negative breast cancers: unique clinical presentations and outcomes. Ann Surg Oncol. 2010 Oct; 17 Suppl 3:384-90. Epub 2010 Sep 19.
    View PubMed
  59. Stucky CC, Gray RJ, Wasif N, Dueck AC, Pockaj BA. Increase in contralateral prophylactic mastectomy: echoes of a bygone era? Surgical trends for unilateral breast cancer. Ann Surg Oncol. 2010 Oct; 17 Suppl 3:330-7. Epub 2010 Sep 19.
    View PubMed
  60. Chakkera HA, Knowler WC, Devarapalli Y, Weil EJ, Heilman RL, Dueck A, Mulligan DC, Reddy KS, Moss AA, Mekeel KL, Mazur MJ, Hamawi K, Castro JC, Cook CB. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. Clin J Am Soc Nephrol. 2010 Sep; 5(9):1669-75. Epub 2010 Jun 17.
    View PubMed
  61. Pockaj BA, Wasif N, Dueck AC, Wigle DA, Boughey JC, Degnim AC, Gray RJ, McLaughlin SA, Northfelt DW, Sticca RP, Jakub JW, Perez EA. Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look? Ann Surg Oncol. 2010 Sep; 17(9):2419-26. Epub 2010 Mar 16.
    View PubMed
  62. Reinholz MM, Zinnen SP, Dueck AC, Dingli D, Reinholz GG, Jonart LA, Kitzmann KA, Bruzek AK, Negron V, Abdalla AK, Arendt BK, Croatt AJ, Sanchez-Perez L, Sebesta DP, Lonnberg H, Yoneda T, Nath KA, Jelinek DF, Russell SJ, Ingle JN, Spelsberg TC, Dixon HB, A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone. 2010 Jul; 47(1):12-22. Epub 2010 Mar 15.
    View PubMed
  63. Jatoi A, Ritter HL, Dueck A, Nguyen PL, Nikcevich DA, Luyun RF, Mattar BI, Loprinzi CL. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer. 2010 May; 68(2):234-9. Epub 2009 Aug 08.
    View PubMed
  64. Kearns AE, Northfelt DW, Dueck AC, Atherton PJ, Dakhil SR, Rowland KM Jr, Fuloria J, Flynn PJ, Dentchev T, Loprinzi CL. Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8. Support Care Cancer. 2010 Mar; 18(3):321-8. Epub 2009 May 27.
    View PubMed
  65. Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kahanic SP, Gross HM, Patel TA, Palmieri FM, Dueck AC. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Ann Oncol. 2010 Feb; 21(2):269-74. Epub 2009 Nov 09.
    View PubMed
  66. Hu LS, Baxter LC, Pinnaduwage DS, Paine TL, Karis JP, Feuerstein BG, Schmainda KM, Dueck AC, Debbins J, Smith KA, Nakaji P, Eschbacher JM, Coons SW, Heiserman JE. Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas. AJNR Am J Neuroradiol. 2010 Jan; 31(1):40-8. Epub 2009 Sep 12.
    View PubMed
  67. Reinholz MM, Eckel-Passow JE, Anderson SK, Asmann YW, Zschunke MA, Oberg AL, McCullough AE, Dueck AC, Chen B, April CS, Wickham-Garcia E, Jenkins RB, Cunningham JM, Jen J, Perez EA, Fan JB, Lingle WL. Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL(R) platform. BMC Med Genomics. 2010; 3:60. Epub 2010 Dec 20.
    View PubMed
  68. Grover M, Anderson M, Gupta R, Haden M, Hartmark-Hill J, Morski LM, Sarmiento P, Dueck A. Increased osteoporosis screening rates associated with the provision of a preventive health examination. J Am Board Fam Med. 2009 Nov-Dec; 22(6):655-62.
    View PubMed
  69. Shrestha B, Sekiguchi H, Colby TV, Graziano P, Aubry MC, Smyrk TC, Feldman AL, Cornell LD, Ryu JH, Chari ST, Dueck AC, Yi ES. Distinctive pulmonary histopathology with increased IgG4-positive plasma cells in patients with autoimmune pancreatitis: report of 6 and 12 cases with similar histopathology. Am J Surg Pathol. 2009 Oct; 33(10):1450-62.
    View PubMed
  70. Stucky CC, McLaughlin SA, Dueck AC, Gray RJ, Giurescu ME, Carpenter SG, Grimsby GM, Apsey HA, Pockaj BA. Does magnetic resonance imaging accurately predict residual disease in breast cancer? Am J Surg. 2009 Oct; 198(4):547-52.
    View PubMed
  71. Grimsby GM, Gray R, Dueck A, Carpenter S, Stucky CC, Aspey H, Giurescu ME, Pockaj B. Is there concordance of invasive breast cancer pathologic tumor size with magnetic resonance imaging? Am J Surg. 2009 Oct; 198(4):500-4.
    View PubMed
  72. Carpenter SG, Stucky CC, Dueck AC, Grimsby G, Giurescu M, Apsey H, Gray RJ, Pockaj BA. Scientific Presentation Award: The impact of magnetic resonance imaging on surgical treatment of invasive breast cancer. Am J Surg. 2009 Oct; 198(4):475-81.
    View PubMed
  73. Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, Baxter LC, Rapcsak SZ, Shi J, Woodruff BK, Locke DE, Snyder CH, Alexander GE, Rademakers R, Reiman EM. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med. 2009 Jul 16; 361(3):255-63.
    View PubMed
  74. Pockaj BA, Degnim AC, Boughey JC, Gray RJ, McLaughlin SA, Dueck AC, Perez EA, Halyard MY, Frost MH, Cheville AL, Sloan JA. Quality of life after breast cancer surgery: What have we learned and where should we go next? J Surg Oncol. 2009 Jun 1; 99(7):447-55.
    View PubMed
  75. Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil SR, Perez EA. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol. 2009 Jun 1; 27(16):2638-44. Epub 2009 Apr 06.
    View PubMed
  76. Sprangers MA, Sloan JA, Veenhoven R, Cleeland CS, Halyard MY, Abertnethy AP, Baas F, Barsevick AM, Bartels M, Boomsma DI, Chauhan C, Dueck AC, Frost MH, Hall P, Klepstad P, Martin NG, Miaskowski C, Mosing M, Movsas B, Van Noorden CJ, Patrick DL, Pedersen The establishment of the GENEQOL consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes. Twin Res Hum Genet. 2009 Jun; 12(3):301-11.
    View PubMed
  77. Pipe TB, Bortz JJ, Dueck A, Pendergast D, Buchda V, Summers J. Nurse leader mindfulness meditation program for stress management: a randomized controlled trial. J Nurs Adm. 2009 Mar; 39(3):130-7.
    View PubMed
  78. Loprinzi CL, Dueck AC, Khoyratty BS, Barton DL, Jafar S, Rowland KM Jr, Atherton PJ, Marsa GW, Knutson WH, Bearden JD 3rd, Kottschade L, Fitch TR. A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol. 2009 Mar; 20(3):542-9. Epub 2009 Jan 06.
    View PubMed
  79. Conley SP, Humphreys MR, Desai PJ, Castle EP, Dueck AC, Ferrigni RG, Andrews PE. Laparoscopic radical nephrectomy for very large renal tumors (> or =10 cm): is there a size limit? J Endourol. 2009 Jan; 23(1):57-61.
    View PubMed
  80. Halyard M, Pisansky T, Dueck A, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil S, Perez E. Radiotherapy and Adjuvant Trastuzumab in Stage I-IIA Breast Cancer: Tolerability and Adverse Event Data From the North Central Cancer Treatment Group Phase I Trial N9831. J Clin Oncol. 2009; 27:2638-44.
    View PubMed
  81. Carpenter S, Pockaj B, Dueck A, Gray R, Kurtz D, Sekulic A, Casey W. Factors influencing time between biopsy and definitive surgery for malignant melanoma: do they impact clinical outcome? Am J Surg. 2008 Dec; 196(6):834-42; discussion 842-3.
    View PubMed
  82. Suman VJ, Dueck A, Sargent DJ. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Cancer Invest. 2008 Jun; 26(5):439-44.
    View PubMed
  83. Revicki DA, Erickson PA, Sloan JA, Dueck A, Guess H, Santanello NC, Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. Interpreting and reporting results based on patient-reported outcomes. Value Health. 2007 Nov-Dec; 10 Suppl 2:S116-24.
    View PubMed
  84. Dueck AC, Sloan JA. Meeting on the FDA draft guidance on patient-reported outcomes. Value Health. 2007 Nov-Dec; 10 Suppl 2:S64-5.
    View PubMed
  85. Sloan JA, Dueck AC, Erickson PA, Guess H, Revicki DA, Santanello NC, Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. Analysis and interpretation of results based on patient-reported outcomes. Value Health. 2007 Nov-Dec; 10 Suppl 2:S106-15.
    View PubMed
  86. Garrison LP Jr, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 2007 Aug 1; 110(3):489-98.
    View PubMed
  87. Mularski RA, Rosenfeld K, Coons SJ, Dueck A, Cella D, Feuer DJ, Lipscomb J, Karpeh MS Jr, Mosich T, Sloan JA, Krouse RS. Measuring outcomes in randomized prospective trials in palliative care. J Pain Symptom Manage. 2007 Jul; 34(1 Suppl):S7-S19. Epub 2007 May 25.
    View PubMed
  88. Loprinzi CL, Kugler JW, Barton DL, Dueck AC, Tschetter LK, Nelimark RA, Balcueva EP, Burger KN, Novotny PJ, Carlson MD, Duane SF, Corso SW, Johnson DB, Jaslowski AJ. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol. 2007 Jan 20; 25(3):308-12. Epub 2006 Dec 04.
    View PubMed
  89. Loprinzi C, Kugler J, Barton D, Dueck A, Tschetter L, Nelimark R, Balcueva E, Burger K, Novotny P, Carlson M, Duane S, Corso S, Johnson D, Jaslowski A. A phase III randomized trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone; NCCTG N03C5. J Clin Oncol. 2007; 25:308-12.
    View PubMed
  90. Halyard MY, Frost MH, Dueck A, Sloan JA. Is the use of QOL data really any different than other medical testing? Curr Probl Cancer. 2006 Nov-Dec; 30(6):261-71.
    View PubMed
  91. Dueck A, Novotny PJ. Dealing with multiple endpoints. Curr Probl Cancer. 2006 Nov-Dec; 30(6):298-306.
    View PubMed
  92. Halyard MY, Frost MH, Dueck A. Integrating QOL assessments for clinical and research purposes. Curr Probl Cancer. 2006 Nov-Dec; 30(6):319-30.
    View PubMed
  93. Sloan JA, Frost MH, Berzon R, Dueck A, Guyatt G, Moinpour C, Sprangers M, Ferrans C, Cella D, Clinical Significance Consensus Meeting Group. The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer. 2006 Oct; 14(10):988-98. Epub 2006 Jun 23.
    View PubMed
  94. Kamath C, Dueck A. Incorporating clinical significance into a study. Curr Probl Cancer. 2005 Nov-Dec; 29(6):306-16.
    View PubMed
  95. Huntington JL, Dueck A. Handling missing data. Curr Probl Cancer. 2005 Nov-Dec; 29(6):317-25.
    View PubMed
  96. Mandrekar S, Dueck A. Future directions in QOL research. Curr Probl Cancer. 2005 Nov-Dec; 29(6):343-51.
    View PubMed
  97. Dueck A, Lohr S. Robust estimation of multivariate covariance components. Biometrics. 2005 Mar; 61(1):162-9.
    View PubMed
  98. Sloan J, Frost M, Berzon R, Dueck A, Guyatt G, Moinpour C, Sprangers M, Ferrans C, Cella D The Clinical Significance of Quality of Life Assessments in Oncology: A Summary for Clinicians Cancer. 2005.
    View PubMed
  99. Sloan JA, Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat. 2004 Feb; 14(1):73-96.
    View PubMed